ontada®

How biomarkers are impacting decisions across the product lifecycle

Each person's cancer possesses a distinct pattern of biomarkers that can play a pivotal role in treatment decisions

Biomarkers

Biological molecules found in blood, other body fluids, or tissues that reflect signs of a normal or abnormal process, or of a condition or disease[1]

How biomarkers have evolved & grown in use[2,3,4]

Origin

1950s
Version of term, "biomarker," originates

1980s
"Biomarker" began wide use

1998
"Biomarker" offcially recognized by National Institutes of Health (NIH)

Research growth[5]

Number of publications referencing "biomarker" in the title or abstract



Number of publications referencing "biomarker" & "immune" in the title of an abstract



Clinical trial growth

Oncology clinical trials that involved use of biomarkers



Testing growth

Percentage of cancer patients who had biomarker testing[6]



Percentage of early-stage non-small cell lung cancer (eNSCLC) patients receiving biomarker testing[7]



Percentage of advanced/metastatic Nonsquamous NSCLC patients receiving biomarker testing



In the last five years, more than half of the 62 cancer drugs introduced required or recommended biomarker testing

How biomarkers are impacting decisions across the product lifecycle

Discovery
Identify potential drug targets or stratify patients based on genetic mutations or gene expression patterns to identify specific cancer subtypes that may respond differently to treatment

Clinical development
Select patients who are more likely to benefit from a targeted therapy, enabling more precise patient selection & increasing the chances of demonstrating efficacy in clinical trials

Launch / Commercialization
Tailor efforts toward specific patient populations based on their molecular profile for whom the drug is most appropriate

Post-marketing approval & surveillance
Assess the drug's performance and identify any potential safety concerns in specific patient populations that may not have been captured during clinical trials

How biomarkers are being used in precision oncology today

Today, biomarkers are commonly used in precision oncology to

- Assess cancer risk, diagnosis, prognosis
- Predict rate of disease growth and spread
- Identify patients based on their molecular profile for clinical trial inclusion
- Deliver personalized care based on biomarker status
- Look for signs of cancer recurrence
- Guide treatment selection including targeted therapies and immunotherapies
- Monitor treatment effectiveness

What patients and providers say about biomarker testing

In patient & provider surveys[10,11]

89%
of providers agree that biomarker testing enables better treatment recommendation

85%
of providers agree that enhancing access to biomarker testing will improve health equity

77%
of patients said biomarker testing helped treat their cancer better

How legislators are reacting to biomarker trends[12]

- 18 states have enacted legislation requiring coverage in both public & private insurance plans[13]
- 22 states are opening, or looking at how to open, access to panel biomarker testing[14]
- CMS covers next-generation sequencing as a diagnostic laboratory test when performed in a clinical laboratory improvement amendment (clia)-certified laboratory or ordered by a treating physician under specific conditions[15]
- In 2023, only six states required some level of coverage for whole-genome sequencing and next-generation sequencing[16]

What the future of biomarkers in oncology looks like[17]

- Driven by increased access to precision medicine therapeutics, the global clinical oncology biomarker testing market is predicted by a 2024 report to reach $12.6 billion by 2028[18]
- Biomarker testing is expected to be the core of oncologic care
- With tech advances, testing will become more sensitive & specific
- Cancer diagnoses may be possible from liquid biopsy
- Testing may increasingly be used to determine a person's risk of developing cancer

How Ontada integrates biomarkers into our technology & RWD

Biomarker information is integrated into providers' workflow in our oncology EHR, iKnowMed®, helping providers access at the point of need

Patient biomarker data

Diagnosis-level biomarker test & lab recommendations at point of care

Evidence-based value pathways

Biomarker ordering and workflow support in selecting & ordering molecular tests

In turn, testing and treatment patterns based on biomarker information are reflected in our real-world data (RWD), which life sciences companies can use in their commercialization strategies.

This is how we advance cancer care together.

To learn more about how Ontada can support your real-world data and research needs, get in touch with one of our oncology research experts for an introductory call.

Learn more

ontada®

Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the core belief that precise insights - delivered exactly at the point of need - can save more patients' lives. We connect the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by all top 15 global life sciences companies. Our work helps accelerate innovation and powers the future of cancer care. For more information, visit ontada.com.

References

1 "Biomarker, NCI Dictionary of Cancer Terms," National Cancer Institute. Click Here.
2 Biomarkers: Promising and valuable tools towards diagnosis, prognosis and treatment of Covid-19 and other diseases," National Library of Medicine, February 2023. Click Here.
3 Special Report: The Evolution of Biomarker Use in Clinical Trials for Cancer Treatments, Precision Medicine Quarterly, December 8, 2020. Click Here.
4 New Survey: Top Barriers to Biomarker Use in Cancer Care Include Coverage and Cost Concerns, American Cancer Society Cancer Action Network, December 2, 2021. Click Here.
5 Clinically relevant biomarker strategies in drug development, News-Medical Life Sciences, Jan. 9, 2023. Click Here.
6 Cancer Patients and Survivors Overwhelming Agree Biomarker Testing Improved their Treatment. American Cancer Society Cancer Action Network. Click Here.
7 Real-World Data Shows Significant Increase of Biomarker Testing in Past Decade for NSCLC. Targeted Oncology, May 8, 2023. Click Here.
8 Biomarker Testing for Patients With Advanced/Metastatic Nonsquamous NSCLC in the United States of America, 2015 to 2021. JTO Clinical and Research Reports, June, 2022. Click Here.
9 Predictors of biomarker testing among patients (pts) with metastatic non-small cell lung cancer (mNSCLC), Journal of Clinical Oncology, June 2022. Click Here.
10 Cancer Patients and Survivors Overwhelming Agree Biomarker Testing Improved their Treatment. American Cancer Society Cancer Action Network. Click Here.
11 New Survey: Top Barriers to Biomarker Use in Cancer Care Include Coverage and Cost Concerns, American Cancer Society Cancer Action Network, December 2, 2021. Click Here.
12 Biomarker legislation could improve patient access in 2024. Healthcare IT News. December 29, 2023. Click Here.
13 "The State of State Biomarker Testing Insurance Coverage Laws," Journal of American Medical Association, May 13, 2024. Click Here.
14 "Biomarker legislation could improve patient access in 2024," Healthcare IT News, Dec. 29, 2023. Click Here.
15 Next Gen Sequencing (NGS) for Medicare Beneficiaries with Advanced Cancer, CMS.gov. Click Here.
16 Fostering Access to Next-Generation Sequencing to Shorten the Rare Disease Diagnostic Odyssey, Alexion, AstraZeneca Rare Disease white paper, October 2023. Click Here.
17 Biomarker Testing and the Future of Oncology. Texas Oncology. April 13, 2023. Click Here.
18 DeciBio Forecasts the Global Clinical Oncology Biomarker Testing Market to Grow at 13% p.a., Reaching ~$12.6B in 2028, Yahoo! Finance, Jan. 3, 2024. Click Here.